Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14498572 | 1.00 | CYP2C19 (0.49) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL10644287 | 0.83 | PGR (0.49) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL6258236 | 0.81 | PGR (0.47) | PGRADRA2AADRA2BHTR2AHRH1 | |
| SCHEMBL3143553 | 0.81 | CYP2C19 (0.52) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL10975235 | 0.81 | MDM2 (0.55) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL8737261 | 0.80 | CYP2C19 (0.71) | CYP2C19MMP1MMP2MMP3MMP7 | |
| SCHEMBL9356364 | 0.79 | CYP2C19 (0.55) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL2405032 | 0.79 | CYP2C19 (0.50) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL6834266 | 0.79 | MDM2 (0.49) | CYP2C19PGRADRA2AADRA2BHTR2A | |
| SCHEMBL31492931 | 0.79 | ATM (0.50) | CYP2C19PGRADRA2AADRA2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61205225-A | — | — | None | — | — | JP | disclosed |
| EP-4426684-B1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | FIRMENICH & CIE (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250042871-A1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | FIRMENICH & CIE (CH) | 2025-02-06 | — | — | US | disclosed |
| EP-4426684-A1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | Firmenich SA (CH) | 2024-09-11 | — | — | EP | disclosed |
| CN-118215656-A | Cyclic acetals and ketals for photoinduction-released active aldehydes and ketones | 弗门尼舍有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023078909-A1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | FIRMENICH SA (CH) | 2023-05-11 | — | — | WO | disclosed |
| US-20230076320-A1 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| CN-114686195-A | High-temperature-resistant corrosion inhibitor for oil field water injection well and preparation method thereof | 中国石油化工股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20200297665-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| EP-3518908-A2 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | Zogenix International Limited (GB) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060732-A2 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| US-20180092864-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0850948-B1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6048842-A | ANTIDIABETIC AGENT | TANABE SEIYAKU CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0850948-A1 | Propiophenone derivatives and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| JP-S61205225-A | PRODUCTION OF KETONE | MITSUBISHI CHEM IND LTD | 1986-09-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076320-A1 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | TPH2, HTR5A, TPH1 | CYP2C19 348/4885PGR 4471/4885ADRA2A 201/4885 |
| US-20180092864-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | PSEN2, EPM2A, TPH2 | CYP2C19 227/4885PGR 3626/4885ADRA2A 462/4885 |
| US-20200297665-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | PSEN2, EPM2A, TPH2 | CYP2C19 227/4885PGR 3626/4885ADRA2A 462/4885 |
| US-20250042871-A1 | CYCLIC ACETALS AND KETALS FOR THE LIGHT-INDUCED RELEASE OF ACTIVE ALDEHYDES AND KETONES | PKM, PKLR, AKR1C1 | CYP2C19 219/4885PGR 3153/4885ADRA2A 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.